BLAINTRAVENOUSSOLUTION
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Albumin (Human) (albumin human) by Octapharma is glycoprotein. First approved in 2006.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Albumin (Human) is a blood-derived plasma protein therapeutic administered intravenously for osmotic regulation and volume expansion. It is the most abundant circulating protein, accounting for >50% of total plasma proteins by weight, and functions in oncotic pressure maintenance (75% of intravascular oncotic effect), drug/hormone transport, and free radical scavenging. The product treats hypovolemia, shock, burns, and protein malnutrition by restoring intravascular volume and colloid osmotic pressure.
$0.013BPart D
LOE ApproachingAs a mature biologic plasma derivative approaching loss of exclusivity, the brand operates in a stable but increasingly commoditized market with limited expansion opportunity and likely declining team investment.
Mechanism of Action
glycoprotein. It has the lowest molecular weight (66,241 Daltons) of all plasma proteins. Because of its three dimensional structure, solutions of albumin have a lower viscosity than solutions of other plasma proteins. This is important since work performed by the heart depends in part on the…
Pharmacologic Class:
Human Serum Albumin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Worked on Albumin (Human) at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.